Advances in therapy
Safety and Tolerability of Twice-Yearly Depemokimab in Patients with Asthma and Chronic Rhinosinusitis with Nasal Polyps: Pooled Results from SWIFT-1/-2 and ANCHOR-1/-2.
Daniel J Jackson, Arnaud Bourdin, Allison Blackorby, Anna Leslie, Anna Vichiendilokkul, Peter Howarth, Natalia Karkoszka, Shigeharu Fujieda, Marjolein Cornet
Published: 202510.1007/s12325-025-03457-4
Abstract
INTRODUCTION: Depemokimab, the first ultra-long-acting respiratory biologic, is under investigation for diseases with underlying type 2 (T2) inflammation. Subcutaneous depemokimab 100 mg was efficacious in patients with T2 asthma characterized by blo…
Preview only. Read the full abstract at the source